• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

New paper on the Open-Access EPAD MRI dataset and processing workflow

2022-07-13News

A new article entitled “The Open-Access European Prevention of Alzheimer’s Dementia (EPAD) MRI dataset and processing workflow” has recently been published in the journal NeuroImage: Clinical. In this article, authors show an overview of the MRI image processing and QC pipeline for the open-access EPAD study. The introduced procedures and results may serve as a reference point for future developments and promote replicability and stability of results on the EPAD cohort. Authors anticipate that this work will help both imaging and non-imaging researchers working on EPAD for an easier understanding and use of the shared data.

Congratulations to Luigi Lorenzini and all co-authors, Silvia Ingala, Alle Meije Wink, Joost P.A. Kuijer, Viktor Wottschel, Mathijs Dijsselhof, Carole H. Sudre, Sven Haller, Jose Luis Molinuevo
Juan Domingo Gispert, David M. Cash, David L. Thomas, Sjoerd B. Vos, Ferran Prados, Jan Petr, Robin Wolz, Alessandro Palombit, Adam J. Schwarz Gael Chetelat, Pierre Payoux, Carol Di Perri, Joanna M. Wardlaw, Giovanni B. Frisoni, Christopher Foley, Nick C. Fox, Craig Ritchie, Cyril Pernet, Adam Waldman, Frederik Barkhof, Henk J.M.M. Mutsaerts!

You can read the paper here.

Abstract:
The European Prevention of Alzheimer Dementia (EPAD) is a multi-center study that aims to characterize the preclinical and prodromal stages of Alzheimer’s Disease. The EPAD imaging dataset includes core (3D T1w, 3D FLAIR) and advanced (ASL, diffusion MRI, and resting-state fMRI) MRI sequences.

Here, we give an overview of the semi-automatic multimodal and multisite pipeline that we developed to curate, preprocess, quality control (QC), and compute image-derived phenotypes (IDPs) from the EPAD MRI dataset. This pipeline harmonizes DICOM data structure across sites and performs standardized MRI preprocessing steps. A semi-automated MRI QC procedure was implemented to visualize and flag MRI images next to site-specific distributions of QC features — i.e. metrics that represent image quality. The value of each of these QC features was evaluated through comparison with visual assessment and step-wise parameter selection based on logistic regression. IDPs were computed from 5 different MRI modalities and their sanity and potential clinical relevance were ascertained by assessing their relationship with biological markers of aging and dementia.

The EPAD v1500.0 data release encompassed core structural scans from 1356 participants 842 fMRI, 831 dMRI, and 858 ASL scans. From 1356 3D T1w images, we identified 17 images with poor quality and 61 with moderate quality. Five QC features — Signal to Noise Ratio (SNR), Contrast to Noise Ratio (CNR), Coefficient of Joint Variation (CJV), Foreground-Background energy Ratio (FBER), and Image Quality Rate (IQR) — were selected as the most informative on image quality by comparison with visual assessment. The multimodal IDPs showed greater impairment in associations with age and dementia biomarkers, demonstrating the potential of the dataset for future clinical analyses.

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
2023-01-16
Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
2022-12-09
Bruno Steinkraus
Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
2022-11-25
New paper defining and discussing the substantial assets of the EPAD project is out!
2022-11-23
New paper using the EPAD data for an analysis of sleep quality and efficiency
2022-11-03
New paper evaluating diabetes in the EPAD Study published in EJN
2022-10-03
Latest News
  • Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
    2023-01-16
  • Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
    2022-12-09
  • Bruno Steinkraus
    Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
    2022-11-25
  • New paper defining and discussing the substantial assets of the EPAD project is out!
    2022-11-23
  • New paper using the EPAD data for an analysis of sleep quality and efficiency
    2022-11-03
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

All data sets from the @IMI_EPAD Longitudinal Cohort Study are available in the @AlzData #ADWorkbench and we're pleased to see that more and more people are using the platform to share & discover #data to accelerate discoveries and innovations in the #Alzheimer's disease field⤵️ twitter.com/AlzData/status…

reply retweet favorite
8:41 am · 2023-01-25
Twitter
EPAD
EPAD
@IMI_EPAD

The Edinburgh Dementia Prevention Summer School 2023 will focus on the latest evidence for #dementia #prevention and promoting good #brainhealth ➡️5-day interactive online course ➡️For clinicians, nurses, health professionals, researchers ➡️Register here edin.ac/3iJNJST twitter.com/WTCRF_Educatio…

reply retweet favorite
1:38 pm · 2023-01-18
Twitter
EPAD
EPAD
@IMI_EPAD

The research team studied data from 1,178 women participating in @IMI_EPAD. ✅The project spanned 10 countries ✅Large and diverse population ✅Wide-range of outcomes at each annual visit The @IMI_EPAD data are available on the @AlzData #ADWorkbench⤵️ ep-ad.org/open-access-da…

reply retweet favorite
7:48 am · 2023-01-16
Twitter
EPAD
EPAD
@IMI_EPAD

Exciting findings showing that Hormone Replacement Therapy use is associated with better memory, cognition and larger brain volumes in later life among women carrying the APOE4 gene. ⬇️ uea.ac.uk/news/-/article…

reply retweet favorite
7:40 am · 2023-01-16
Twitter
EPAD
EPAD
@IMI_EPAD

Hormone Replacement Therapy could help prevent #Alzheimer’s #dementia among women at risk of developing the disease – according to @UEAResearch. The research team used @IMI_EPAD data. @craig_ritchie68 @ProfAMMinihane @IHIEurope @IMI2_NEURONET @AlzData doi.org/10.1186/s13195…

reply retweet favorite
7:37 am · 2023-01-16
Workstream Progress
Workstream 120%
Workstream 232%
Workstream 310%
Workstream 446%
Contact us

Submitclear

Recent Posts
  • Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
  • Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
  • Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
  • New paper defining and discussing the substantial assets of the EPAD project is out!
  • New paper using the EPAD data for an analysis of sleep quality and efficiency
Recent Comments
  • The EPAD genomic data is now available on the Alzheimer’s Disease Workbench on The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
  • ADDI celebrates one year of achievements – Neuronet on ADDI celebrates one year of achievements
  • EPAD dataset is now available on the Alzheimer’s Disease Workbench on The final EPAD dataset is now available on the Alzheimer’s Disease Workbench
  • The final EPAD dataset is now available to the entire research community on The final EPAD dataset is now available to the entire research community
  • The ERC has awarded an ERC grant to identify age-related human blood factors as a therapeutic target for Alzheimer’s disease – Neuronet on New ERC starting grant to identify age-related human blood factors as a therapeutic target for Alzheimer’s disease
Archives
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • January 2022
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • November 2020
  • October 2020
  • September 2020
  • July 2020
  • June 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • June 2015
  • May 2015
  • April 2015
Categories
  • EPAD Academy
  • News
Meta
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT